1. Home
  2. MGNX vs AUDC Comparison

MGNX vs AUDC Comparison

Compare MGNX & AUDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

N/A

Current Price

$2.39

Market Cap

262.4M

Sector

Health Care

ML Signal

N/A

Logo AudioCodes Ltd.

AUDC

AudioCodes Ltd.

N/A

Current Price

$8.41

Market Cap

247.7M

Sector

Utilities

ML Signal

N/A

Company Overview

Basic Information
Metric
MGNX
AUDC
Founded
2000
1992
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Telecommunications Equipment
Sector
Health Care
Utilities
Exchange
Nasdaq
Nasdaq
Market Cap
262.4M
247.7M
IPO Year
2013
2000

Fundamental Metrics

Financial Performance
Metric
MGNX
AUDC
Price
$2.39
$8.41
Analyst Decision
Buy
Analyst Count
7
0
Target Price
★ $8.00
N/A
AVG Volume (30 Days)
★ 995.8K
108.9K
Earning Date
11-24-2026
11-04-2026
Dividend Yield
N/A
★ 4.74%
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $149,500,000.00
N/A
Revenue This Year
N/A
$3.05
Revenue Next Year
N/A
$3.87
P/E Ratio
★ N/A
$23.06
Revenue Growth
N/A
★ N/A
52 Week Low
$1.32
$6.95
52 Week High
$5.08
$11.74

Technical Indicators

Market Signals
Indicator
MGNX
AUDC
Relative Strength Index (RSI) 34.86 30.49
Support Level $1.71 $8.27
Resistance Level $3.46 $8.63
Average True Range (ATR) 0.30 0.45
MACD 0.01 -0.38
Stochastic Oscillator 26.15 22.05

Price Performance

Historical Comparison
MGNX
AUDC

About MGNX MacroGenics Inc.

Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.

About AUDC AudioCodes Ltd.

AudioCodes Ltd provides voice communications solutions for enterprises, contact centers, and service providers, including voice infrastructure, cloud-based platforms, and Voice AI applications. Its AudioCodes Live Platform is a cloud-based service delivery platform that enables provisioning, management, and operation of voice and AI-based communication services, including PSTN connectivity and integration with platforms such as Microsoft Teams, Webex Calling, and Zoom Phone. The company's solutions are organized into three layers: voice infrastructure and devices, cloud-based platforms, and Voice AI applications for contact center and productivity use cases. It also offers management tools such as One Voice Operations Center (OVOC), Device Manager, and AudioCodes Routing Manager (ARM).

Share on Social Networks: